Temperament and character influence on depression treatment outcome.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 14 08 2018
revised: 07 03 2019
accepted: 07 04 2019
pubmed: 22 4 2019
medline: 6 2 2020
entrez: 22 4 2019
Statut: ppublish

Résumé

personality features have been repeatedly associated with depression treatment outcome in Major Depressive Disorder (MDD), however conclusive results are still lacking. Moreover, as for Bipolar Disorder (BD), results are only few and preliminary. the aim of the present study was to perform an exploratory investigation of the influence of personality traits as assessed by the Temperament and Character Inventory (TCI), on principal depression treatment outcomes (non remission, non response and resistance). 743 mood disorders patients (455 MDD (61.24%) and 288 BD (38.76%)) were recruited in the context of 6 European studies. Generalized logit models were performed to test the effects of TCI dimensions on treatment outcomes, considering possible confounders such as age, gender and education. Positive results were controlled for comorbidities (anxiety and substance use disorders) as well. MDD Non-Remitters showed high Harm Avoidance (HA) and Self Transcendence (ST) (p = 0.0004, d = 0.40; p = 0.007, d = 0.36 respectively) and low Persistence (P) and Self Directedness (SD) (p = 0.05; d = 0.18; p = 0.002, d = 0.40, respectively); MDD Non-Responders showed a slightly different profile with high HA and low Reward Dependence (RD) and SD; finally, MDD Resistants showed low RD, P and Cooperativeness (C). In BD patients, only higher HA in non response was observed. the retrospective cross-sectional design, the TCI assessment regardless of the mood state and the small number of bipolar patients represent the main limitations. specific TCI personality traits are associated with depression treatment outcome in MDD patients. The inclusion of such personality traits, together with other socio-demographic and clinical predictors, could ameliorate the accuracy of the prediction models available to date.

Sections du résumé

BACKGROUND
personality features have been repeatedly associated with depression treatment outcome in Major Depressive Disorder (MDD), however conclusive results are still lacking. Moreover, as for Bipolar Disorder (BD), results are only few and preliminary.
AIM
the aim of the present study was to perform an exploratory investigation of the influence of personality traits as assessed by the Temperament and Character Inventory (TCI), on principal depression treatment outcomes (non remission, non response and resistance).
METHODS
743 mood disorders patients (455 MDD (61.24%) and 288 BD (38.76%)) were recruited in the context of 6 European studies. Generalized logit models were performed to test the effects of TCI dimensions on treatment outcomes, considering possible confounders such as age, gender and education. Positive results were controlled for comorbidities (anxiety and substance use disorders) as well.
RESULTS
MDD Non-Remitters showed high Harm Avoidance (HA) and Self Transcendence (ST) (p = 0.0004, d = 0.40; p = 0.007, d = 0.36 respectively) and low Persistence (P) and Self Directedness (SD) (p = 0.05; d = 0.18; p = 0.002, d = 0.40, respectively); MDD Non-Responders showed a slightly different profile with high HA and low Reward Dependence (RD) and SD; finally, MDD Resistants showed low RD, P and Cooperativeness (C). In BD patients, only higher HA in non response was observed.
LIMITATIONS
the retrospective cross-sectional design, the TCI assessment regardless of the mood state and the small number of bipolar patients represent the main limitations.
CONCLUSION
specific TCI personality traits are associated with depression treatment outcome in MDD patients. The inclusion of such personality traits, together with other socio-demographic and clinical predictors, could ameliorate the accuracy of the prediction models available to date.

Identifiants

pubmed: 31005789
pii: S0165-0327(18)31789-0
doi: 10.1016/j.jad.2019.04.031
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

464-474

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Martina Balestri (M)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.

Stefano Porcelli (S)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.

Daniel Souery (D)

Laboratoire de Psychologie Médicale, Université Libre de Bruxelles, Centre Européen de Psychologie Médicale-PsyPluriel, Brussels, Belgium.

Siegfried Kasper (S)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Dimitris Dikeos (D)

Department of Psychiatry, Athens University Medical School, Athens, Greece.

Panagiotis Ferentinos (P)

Department of Psychiatry, Athens University Medical School, Athens, Greece.

George N Papadimitriou (GN)

Department of Psychiatry, Athens University Medical School, Athens, Greece.

Dan Rujescu (D)

University Clinic for Psychiatry, Psychotherapy and Psychosomatic, Martin-Luther-University Halle-Wittenberg, Germany.

Giovanni Martinotti (G)

Department of Neuroscience, Imaging, Scienze Cliniche, University "G.d'Annunzio", Chieti, Italy.

Marco Di Nicola (M)

Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Catholic University of Sacred Heart, Rome, Italy.

Luigi Janiri (L)

Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Catholic University of Sacred Heart, Rome, Italy.

Elisabetta Caletti (E)

Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Gian Mario Mandolini (GM)

Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Alessandro Pigoni (A)

Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Riccardo Augusto Paoli (RA)

Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Matteo Lazzaretti (M)

Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Paolo Brambilla (P)

Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Michela Sala (M)

Department of Mental Health, Azienda Sanitaria Locale Alessandria, Alessandria, Italy.

Vera Abbiati (V)

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Marcella Bellani (M)

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy; UOC Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Italy.

Cinzia Perlini (C)

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy; UOC Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Italy.

Maria Gloria Rossetti (MG)

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy; UOC Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Italy.

Sara Piccin (S)

Unit of Psychiatry, Department of Medicine (DAME), University of Udine, Udine, Italy.

Carolina Bonivento (C)

Unit of Psychiatry, Department of Medicine (DAME), University of Udine, Udine, Italy.

Dora Fabbro (D)

Department of Laboratory Medicine, Institute of Medical Genetics, University of Udine, Italy.

Giuseppe Damante (G)

Department of Laboratory Medicine, Institute of Medical Genetics, University of Udine, Italy.

Clarissa Ferrari (C)

Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio FBF, Brescia, Italy.

Roberta Rossi (R)

Unit of Psychiatry, IRCCS Istituto Centro San Giovanni di Dio FBF, Brescia, Italy.

Laura Pedrini (L)

Unit of Psychiatry, IRCCS Istituto Centro San Giovanni di Dio FBF, Brescia, Italy.

Francesco Benedetti (F)

Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy, University Vita-Salute San Raffaele, Milan, Italy.

Stuart Montgomery (S)

Imperial College, University of London, London, United Kingdom.

Joseph Zohar (J)

Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Julien Mendlewicz (J)

Université Libre de Bruxelles, Brussels, Belgium.

Alessandro Serretti (A)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy. Electronic address: alessandro.serretti@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH